01:04 , Dec 8, 2017 |  BC Innovations  |  Translation in Brief

ADAM and Ephrin

An October study in Nature Medicine from researchers at Harvard Medical School and the University of Montreal has shown inhibiting the cell surface protease ADAM10 could treat a form of idiopathic pulmonary fibrosis mediated by...
19:02 , Oct 24, 2017 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Mouse studies suggest inhibiting ADAM10 could help treat idiopathic pulmonary fibrosis (IPF). In a mouse model of IPF, an ADAM10 inhibitor tool compound decreased fibrosis in the lung and increased survival compared...
20:12 , Sep 26, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest inhibiting ADAM10 with INCB7839 could help treat brain cancer. In a mouse model of high-grade glioma, knockout of NLGN3 -- which is activated by ADAM10-mediated cleavage from synaptic membranes...
16:25 , Sep 20, 2017 |  BC Extra  |  Preclinical News

Inhibiting ADAM10 could help treat brain cancer

In a paper published in Nature , researchers at Stanford University and colleagues showed that glioma growth is dependent on neuroligin 3 (NLGN3) , and that inhibiting ADAM metallopeptidase domain 10 (ADAM10) reduced NLGN3 shedding...
21:45 , Jul 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Insider signaling

With evidence mounting that cell surface receptors keep signaling after they are internalized, a Takeda-backed study from Monash University has shown how the phenomenon could solve the riddle of why antagonists of the substance P...
14:18 , Dec 22, 2016 |  BC Innovations  |  Targets & Mechanisms

Opportunity Knocks

Despite its continued emphasis on tapping external innovation for new opportunities, industry is still leaving on the table scores of unexploited drug targets identified at universities, according to an analysis of BioCentury’s BCIQ: BioCentury Online...
07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Panel of 12 hippocampal proteins to diagnose early stage Alzheimer's disease

Biomarkers TECHNOLOGY: Tissue markers Hippocampal expression of a panel of 12 proteins could help diagnose early stage AD. Microarray analyses of postmortem brain tissue samples from six individuals previously not diagnosed with AD identified associations...
07:00 , Aug 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: ADAM metallopeptidase domain 10 (ADAM10)

Cancer INDICATION: Colorectal cancer; gastric cancer Patient sample and mouse studies suggest inhibiting a high molecular weight form of ADAM10 could help treat colorectal and gastric cancers. In tissue samples from colon cancer patients or...
07:00 , Sep 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: ADAM metallopeptidase domain 10 (ADAM10); amyloid precursor protein (APP)

Neurology INDICATION: Fragile X syndrome In vitro and mouse studies suggest inhibiting ADAM10 could help treat fragile X syndrome. Levels of soluble APPα, an ADAM10-mediated cleavage product of APP, were higher in lymphoblastoid cells from...
07:00 , Jul 23, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Peroxisome proliferation activated receptor (PPAR) α; retinoid X receptor (RXR)

Neurology INDICATION: Alzheimer's disease (AD) In vitro and mouse studies suggest agonists of PPARα and its co-activator RXR could help treat AD. In a mouse model of AD, PPARα knockout increased β amyloid (Aβ) deposition...